APA

Borchmann P., Fosså A., Długosz-Danecka M., Böll B., Dietlein M., Kobe C., Goergen H. & Engert A. (2018). The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered. : HemaSphere.

Chicago

Borchmann Peter, Fosså Alexander, Długosz-Danecka Monika, Böll Boris, Dietlein Markus, Kobe Carsten, Goergen Helen and Engert Andreas. 2018. The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered. : HemaSphere.

Harvard

Borchmann P., Fosså A., Długosz-Danecka M., Böll B., Dietlein M., Kobe C., Goergen H. and Engert A. (2018). The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered. : HemaSphere.

MLA

Borchmann Peter, Fosså Alexander, Długosz-Danecka Monika, Böll Boris, Dietlein Markus, Kobe Carsten, Goergen Helen and Engert Andreas. The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered. : HemaSphere. 2018.